Levin G M, Grum C, Eisele G
Albany College of Pharmacy, New York 12208, USA.
J Clin Psychopharmacol. 1998 Jun;18(3):237-40. doi: 10.1097/00004714-199806000-00009.
Prescription doses of nonsteroidal antiinflammatory agents have been shown to decrease clearance and increase plasma concentrations of lithium. This study was designed to evaluate whether over-the-counter (OTC) doses of naproxen sodium or acetaminophen have the same potential to affect lithium concentration. This was a prospective, crossover, 3-phase study conducted at the Clinical Pharmacology Studies Unit of the Albany Medical Center Hospital during July and August of 1995. The 3-phase study comprised the following: phase 1, lithium carbonate (300 mg every 12 hours) alone for 7 days; phase 2, lithium and either naproxen sodium (220 mg every 8 hours) or acetaminophen (650 mg every 6 hours) for 5 days; and phase 3, a 2-day washout period followed by a crossover to lithium with the alternate drug (acetaminophen or naproxen sodium) for 5 days. Twelve healthy male volunteers were recruited, nine of whom completed the study and were included in the statistical analysis. Mean (+/-SD) plasma lithium concentrations for subjects in treatment group 1 (lithium in phase 1, lithium and naproxen sodium in phase 2, lithium and acetaminophen in phase 3) were 0.38 (+/-0.11), 0.40 (+/-0.07), and 0.36 (+/-0.11) mEq/L, respectively. Mean plasma lithium concentrations for subjects in treatment group 2 (lithium in phase 1, lithium and acetaminophen in phase 2, lithium and naproxen sodium in phase 3) were 0.43 (+/-0.05), 0.48 (+/-0.10), and 0.48 (+/-0.05) mEq/L, respectively. One-way repeated-measures analysis of variance and paired t-test showed no statistically significant differences (p>0.05) in plasma lithium concentrations during any phase of the study. The results of this study demonstrated that OTC doses of naproxen sodium and acetaminophen did not increase plasma lithium concentrations in these volunteers when taken for short periods of time.
已证明非甾体抗炎药的处方剂量会降低锂的清除率并提高其血浆浓度。本研究旨在评估非处方(OTC)剂量的萘普生钠或对乙酰氨基酚是否具有同样影响锂浓度的可能性。这是一项前瞻性、交叉、三阶段研究,于1995年7月和8月在奥尔巴尼医学中心医院临床药理学研究室进行。三阶段研究包括:第一阶段,单独服用碳酸锂(每12小时300毫克)7天;第二阶段,服用锂和萘普生钠(每8小时220毫克)或对乙酰氨基酚(每6小时650毫克)5天;第三阶段,为期2天的洗脱期,之后交叉服用锂和另一种药物(对乙酰氨基酚或萘普生钠)5天。招募了12名健康男性志愿者,其中9人完成了研究并纳入统计分析。治疗组1(第一阶段服用锂,第二阶段服用锂和萘普生钠,第三阶段服用锂和对乙酰氨基酚)受试者的平均(±标准差)血浆锂浓度分别为0.38(±0.11)、0.40(±0.07)和0.36(±0.11)毫当量/升。治疗组2(第一阶段服用锂,第二阶段服用锂和对乙酰氨基酚,第三阶段服用锂和萘普生钠)受试者的平均血浆锂浓度分别为0.43(±0.05)、0.48(±0.10)和0.48(±0.05)毫当量/升。单向重复测量方差分析和配对t检验表明,在研究的任何阶段,血浆锂浓度均无统计学显著差异(p>0.05)。本研究结果表明,在这些志愿者短期服用时,非处方剂量的萘普生钠和对乙酰氨基酚不会增加血浆锂浓度。